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Health in Action
The Challenge of Managing Non-
Communicable Diseases in Sub-
Saharan Africa
In sub-Saharan Africa (SSA), 
communicable diseases, particularly 
HIV/AIDS, tuberculosis (TB), and 
malaria, are still responsible for 
the greatest burden of morbidity 
and mortality [1]. However, non-
communicable diseases (NCDs) are 
becoming a signiﬁcant burden [1]. 
The Global Burden of Disease Study, 
conducted in 2001, showed that 20% 
of deaths in SSA were due to NCDs 
[2], and this burden is predicted 
to rise to 40% by 2020 [3]. Obesity, 
hypertension, diabetes mellitus, 
cardiovascular disease, asthma, 
chronic obstructive pulmonary disease, 
epilepsy, and mental illness are some 
of the important, chronic NCDs that 
pose signiﬁcant challenges in terms of 
management and follow-up.
How are NCDs currently managed 
in the routine health care settings 
of African countries? In brief, badly. 
Anecdotal reviews point to poorly 
managed health care systems with 
frequent stock interruptions of 
essential drugs [4–6]. Untreated 
hypertension is blamed for high rates 
of stroke morbidity and mortality in 
urban and rural Tanzania [7] and 
rural South Africa [8,9]. Only a small 
proportion of patients with epilepsy 
receive drug treatment at any one time, 
mainly due to poor health care delivery 
systems and unavailability of drugs 
[10]. Even in specialist centres, asthma 
patients are given sub-standard care 
[11] and have poor access to essential 
medications [12]. There is a growing 
burden of diabetes mellitus and its 
associated complications, and many 
patients with type 1 diabetes mellitus 
have extremely short life expectancies 
[13]. 
Some of us know from personal 
experience of running routine 
diabetes and hypertension clinics 
in African hospitals that there are 
no formalised systems of recording 
how many patients have been 
diagnosed and started on therapy, 
how many are retained on therapy, 
or what proportion have died or 
developed complications. We treat 
patients with whatever drugs are 
available, and consider that our 
mission is accomplished. In summary, 
unstructured and unmonitored clinical 
care and little information about 
morbidity or mortality from NCDs are 
mostly the norm in sub-Saharan Africa 
[14]. How do we begin to rectify this 
unsatisfactory situation? A possible 
solution arises out of the existing 
“DOTS” framework for control of TB.
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Summary Points
•  In sub-Saharan Africa, management 
standards for NCDs in public health 
services are poor.
•  With the growing burden of NCDs, 
now is the time to develop and 
implement standardised NCD 
management protocols and systems 
for diagnosis, treatment, monitoring, 
and reporting.
•  DOTS has been the framework 
for tuberculosis control for over a 
decade, allowing structured and well-
monitored services to be delivered 
to millions of tuberculosis patients in 
some of the poorest countries of the 
world.
•  The DOTS model has been successfully 
adapted for the scale-up of ART in 
Malawi, allowing long-term, structured 
treatment to be given to thousands of 
patients.
•  This paper discusses why the DOTS 
paradigm should be adapted for 
NCDs, and, with the “DOTS ﬁve-point 
policy package” as a template, shows 
how this could be implemented and 
rolled out in resource-poor countries, 
with special reference to sub-Saharan 
Africa.
The Health in Action section is a forum for individuals 
or organizations to highlight their innovative 
approaches to a particular health problem.PLoS Medicine  |  www.plosmedicine.org 0860 June 2008  |  Volume 5  |  Issue 6  |  e124
The DOTS Tuberculosis Control 
Framework
In 1994, with the estimated annual 
global TB incidence rate at 8 million 
and the annual TB death rate at 1–2 
million, the World Health Organization 
(WHO) announced a global emergency 
and developed a framework for TB 
control. This framework, based on 
the pioneering work of Dr. Karel 
Styblo [15] and subsequently branded 
“DOTS” by WHO (directly observed 
therapy, short-course), incorporated 
an important ﬁve-point policy package 
(Box 1) [16]. Between 1995 and 2005, 
DOTS was successfully expanded 
to 190 countries, and 26 million 
people, most of them poor, were 
successfully treated with standardised 
anti-tuberculosis drug regimens [17]. 
One of the crucial components of 
DOTS is the registration, recording, 
and reporting format, which is used 
to determine the number of patients 
enrolled for treatment every quarter 
and, 12 months later, the quarterly 
cohort’s subsequent end-of-treatment 
outcomes. Case-ﬁnding and treatment 
outcome data at facility level, collected 
and collated at national level, provide 
country-level information on the 
burden of TB. These data also form 
the basis of national drug forecasting 
and procurement. Well-run TB 
control programmes prevent stock 
interruptions of anti-tuberculosis drugs 
through reliable drug forecasting and 
six-monthly procurement.
Applying the DOTS Paradigm to 
Delivering Antiretroviral Therapy 
in Malawi
In 2001, we advocated to adapt the 
DOTS model for the delivery and 
monitoring of antiretroviral therapy 
(ART) in resource-poor countries [18]. 
The difference between the treatment 
of TB and that of HIV/AIDS is that 
the latter is required life-long. In the 
past six years, this model has been 
developed and used successfully to 
deliver and monitor ART for more 
than 145,000 patients in Malawi, a poor 
country with a gross domestic product 
of less than US$200 per annum [19–
21]. One of the keys to the success of 
this ambitious programme, in a country 
with an under-resourced health care 
system and a grave shortage of skilled 
health care workers, has been the 
simpliﬁcation of management protocols 
to match existing infrastructure. 
Nationwide implementation of these 
protocols has been achieved through 
standardised training, a focus on a 
small number of treatment regimens, 
and quarterly standardised supervision 
and monitoring.
The principles of ART monitoring 
are simple and intuitive and are 
described in more detail in Text S1 
[19,21,22]. Five standardised primary 
treatment outcomes have been 
deﬁned (Box 2), which have proven 
essential for the monitoring of life-
long treatment. Many ART facilities in 
Malawi have now registered between 
1,500 and 2,500 ART patients, and 
health personnel cope satisfactorily 
with this patient load due to regular 
supervision, feedback of results 
from the HIV unit, and a system of 
certiﬁcates of excellence. The standard 
monitoring and supervision system is 
used across the public and the private 
sector in Malawi.
Should the DOTS Paradigm Be 
Adapted for NCDs?
In general, health systems in SSA are 
more oriented to managing acute 
problems than chronic diseases, but 
this will have to change if NCDs are to 
be properly diagnosed, treated, and 
prevented [23]. If life-long ART can be 
managed and monitored by the system 
described in the previous section, 
this paradigm could also be used for 
patients with NCDs. 
A simple, standardised system 
of diagnosis and treatment has the 
advantage that it can be rolled out 
and implemented in all parts of the 
country, thereby improving access 
and facilitating follow-up for all 
patients in need. A standardised 
monitoring and evaluation system 
also has several advantages. First, each 
facility would know, at the end of 
each quarter, how many new patients 
had been diagnosed and registered, 
the cumulative number of patients 
started on treatment, their treatment 
regimens, the number retained 
on treatment, and the number 
with disease-related complications. 
Second, experience from the ART 
programme has shown that well-
designed master cards and registers 
can improve standards of care [22]. 
The implementation of management 
protocols is enforced by requiring set 
ﬁelds to be completed, prompting the 
health worker to assess and monitor 
patients for complications, by clinical 
and/or laboratory means. Third, data 
on the number of patients starting 
therapy every quarter and the total 
number alive and retained on therapy 
allow rational drug forecasting, and 
this would help to prevent the frequent 
interruptions of drug stocks that typify 
health service delivery in much of SSA 
[4–6,8]. In Malawi, such a system has 
allowed rapid scale-up of ART with 
no drug interruptions to date [24]. 
Strategic information generated by 
the system would be pivotal not only 
for the running of the programme, 
but also for advocacy and extended 
support for NCD programmes.
A DOTS strategy has been proposed 
and is being evaluated for managing 
patients with schizophrenia in resource-
poor countries, with a focus on regular 
supplies of antipsychotic medication 
and supervision of drug administration 
[25]. A master card system and patient 
register has been developed for 
monitoring outcomes in asthma [11] 
and smoking cessation services [26]. 
This paradigm, providing standardised 
care and monitoring, could be 
developed for other NCDs. 
Lifestyle modiﬁcation is an 
essential part of this endeavour. As 
HIV prevention is crucially linked 
to ART delivery, if only to curb the 
huge numbers of patients who might 
otherwise become eligible each year for 
treatment, so too is attention to factors 
such as diet, exercise, smoking, and 
alcohol in the prevention of NCDs.
Box 1. Five-Point Policy 
Package of the DOTS 
Framework for Tuberculosis 
Control
• Political  commitment
•  Passive case-ﬁnding using sputum 
smear microscopy in patients 
presenting to health care facilities as 
the cornerstone of diagnosis
• Standardised,  short-course, 
combination anti-tuberculosis 
chemotherapy (with the rifampicin 
component given under direct 
observation by a health care worker, 
community, or family member) 
•  Standardised monitoring and 
evaluation system
•  Uninterrupted drug suppliesPLoS Medicine  |  www.plosmedicine.org 0861 June 2008  |  Volume 5  |  Issue 6  |  e124
Using the DOTS Paradigm for 
Managing NCDs in Sub-Saharan 
Africa
Political commitment. Human and 
ﬁnancial resources, and therefore 
political commitment, are needed to 
develop, implement, and supervise 
standardised approaches.
Passive case-ﬁnding and standardised 
treatment. The only feasible and 
affordable way of identifying patients 
with NCDs is to diagnose and treat 
those who present to health facilities. 
Active case-ﬁnding is too labour-
intensive. Simple diagnostic and 
treatment protocols are needed for 
patients in chronic structured care to 
ensure that standard quality care is 
maintained at all levels of the health 
care system. With life-long NCD 
treatment, directly observed treatment 
by health workers, communities, or 
family members is too onerous, and 
self-administered therapy has to be the 
accepted standard.
Standardised monitoring and 
evaluation, and drug quantiﬁcations. 
At facility level, treatment master 
cards need to be adapted for speciﬁc 
NCDs (Text S2). Registers can be 
similarly adapted and, provided they 
are updated from treatment cards, can 
be used to provide an up-to-date cross-
section of case burden and treatment 
outcomes. Because diabetes mellitus 
and hypertension often occur as co-
morbidities, it would be appropriate to 
combine medications, complications, 
and outcomes in one master card and 
register.
Primary outcomes of alive, dead, 
stopped therapy, lost to follow-up, and 
transferred-out to another treatment 
facility will apply to all NCDs, and 
quarterly collation of data would allow 
regular updating of the denominator 
(how many patients have started 
on therapy in a facility) and the key 
numerator (how many patients are 
retained on therapy in that facility at 
the end of every quarter). There would 
be regular updates of adverse outcomes 
such as death and stopping treatment. 
Active tracing of patients who fail to 
attend clinics would be needed to 
determine the actual primary outcome 
of patients who were “lost to follow-up”. 
For example, an operational research 
study in Malawi showed that 50% 
of ART patients who were classiﬁed 
as “lost to follow-up” had died [27]. 
Patients who transfer out to other 
facilities should be balanced with those 
who transfer in. Typical complications 
that may arise from conditions such as 
diabetes and hypertension should be 
categorised and recorded on master 
cards and in the register; this would 
provide strategic information on 
morbidity. Regular medications should 
be recorded on the master card and 
also on the register, and with quarterly 
and cumulative outcome data, an 
inherent system is thus built to allow 
accurate drug forecasting.
Expanding the DOTS Paradigm for 
NCDs
Within a country, the DOTS paradigm 
for NCDs should be piloted in one 
or two facilities, and lessons learnt 
in these facilities should be used to 
assist national roll-out within the 
public sector. It will be important to 
get private sector participation; this 
has been achieved in Malawi with 
respect to ART (see Text S1). Regular 
supervision, through provincial health 
ofﬁcers, with collection and collation 
of data from all facilities would provide 
strategic information at the national 
level.
As the numbers of patients with 
NCDs grow, it will be useful to build 
real-time electronic data management 
systems where quarterly and cumulative 
analyses can readily be obtained. 
Such electronic systems for managing 
and monitoring ART are already 
being piloted in Malawi, and a similar 
system is being developed for asthma 
care. A culture of applied research 
to determine how best to orientate 
health systems to NCDs must also be 
developed [28,29].
Conclusion
There is a misconception that public 
health is synonymous with infectious 
disease control [30]. NCDs are the 
current public health problem in the 
industrialised world, and will become 
an increasing burden on health services 
in the developing world. Regular, 
accurate, and timely data on case 
numbers and treatment outcomes are a 
sine qua non for proper management. 
At present, no such systems exist in the 
general health sector in sub-Saharan 
Africa, and the simple approach we 
advocate could be the ﬁrst in a series 
of steps (which include attention to 
life-long adherence to medication, 
self-management, peer support, and 
patient associations [31]) designed to 
improve the situation. 
We are proposing a system of 
NCD programme management and 
monitoring at health facility level. Such 
a system would not provide population-
level surveillance on NCD prevalence 
and relevant risk factors, which is an 
ambitious exercise requiring huge 
resource inputs. NCDs are managed 
poorly at facility level in most African 
countries. It is important that ministries 
of health and health care facilities in 
SSA wake up now to the challenge of 
NCDs, so that by the year 2020 they 
are not overtaken by yet other disease 
burdens for which the health systems 
are unprepared and for which there 
are only unreliable estimates on which 
to plan appropriate action.  
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Box 2. Standardised Primary 
ART Outcomes used in Malawi
Alive and on ART: Patient who is alive 
and on ART at the facility where he/she is 
registered.
Dead: Patient who dies from any cause 
while on ART.
Defaulted: Patient who has not attended 
the ART clinic for three months or longer 
for no known reason.
Stopped: Patient who is known to have 
discontinued treatment for any reason.
Transferred-out: Patient who has been 
permanently transferred out to another 
ART treatment facility.PLoS Medicine  |  www.plosmedicine.org 0862 June 2008  |  Volume 5  |  Issue 6  |  e124
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